132 related articles for article (PubMed ID: 33020204)
21. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.
Schilder RJ; Pathak HB; Lokshin AE; Holloway RW; Alvarez RD; Aghajanian C; Min H; Devarajan K; Ross E; Drescher CW; Godwin AK
Gynecol Oncol; 2009 Apr; 113(1):21-7. PubMed ID: 19162309
[TBL] [Abstract][Full Text] [Related]
22. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
[TBL] [Abstract][Full Text] [Related]
23. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
[TBL] [Abstract][Full Text] [Related]
24. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
25. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab in advanced endometrial cancer.
Rubinstein MM; Dickinson S; Narayan P; Zhou Q; Iasonos A; Ma W; Lakhman Y; Makker V
Gynecol Oncol; 2021 Jun; 161(3):720-726. PubMed ID: 33894982
[TBL] [Abstract][Full Text] [Related]
27. Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).
Emons G; Kurzeder C; Schmalfeldt B; Neuser P; de Gregorio N; Pfisterer J; Park-Simon TW; Mahner S; Schröder W; Lück HJ; Heubner ML; Hanker L; Thiel F; Hilpert F
Gynecol Oncol; 2016 Mar; 140(3):450-6. PubMed ID: 26731724
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.
Yamaguchi K; Fuse N; Komatsu Y; Fujii H; Hironaka S; Omuro Y; Muro K; Yasui H; Ueda S; Nishina T; Watanabe M; Ohtsu A
Jpn J Clin Oncol; 2021 May; 51(6):879-885. PubMed ID: 33561262
[TBL] [Abstract][Full Text] [Related]
29. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
Wadlow RC; Hezel AF; Abrams TA; Blaszkowsky LS; Fuchs CS; Kulke MH; Kwak EL; Meyerhardt JA; Ryan DP; Szymonifka J; Wolpin BM; Zhu AX; Clark JW
Oncologist; 2012; 17(1):14. PubMed ID: 22210091
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Slomovitz BM; Jiang Y; Yates MS; Soliman PT; Johnston T; Nowakowski M; Levenback C; Zhang Q; Ring K; Munsell MF; Gershenson DM; Lu KH; Coleman RL
J Clin Oncol; 2015 Mar; 33(8):930-6. PubMed ID: 25624430
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer.
Nakajima TE; Boku N; Doi A; Arai H; Mizukami T; Horie Y; Izawa N; Hirakawa M; Ogura T; Tsuda T; Sunakawa Y
Invest New Drugs; 2020 Apr; 38(2):410-418. PubMed ID: 31020609
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
Saltz LB; Meropol NJ; Loehrer PJ; Needle MN; Kopit J; Mayer RJ
J Clin Oncol; 2004 Apr; 22(7):1201-8. PubMed ID: 14993230
[TBL] [Abstract][Full Text] [Related]
33. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
Chan AT; Hsu MM; Goh BC; Hui EP; Liu TW; Millward MJ; Hong RL; Whang-Peng J; Ma BB; To KF; Mueser M; Amellal N; Lin X; Chang AY
J Clin Oncol; 2005 May; 23(15):3568-76. PubMed ID: 15809453
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting.
Depenni R; Cossu Rocca M; Ferrari D; Azzarello G; Baldessari C; Alù M; Nolé F; Codecà C; Boscolo G; Piccininni M; Cavalieri S; Bossi P
Eur J Cancer; 2019 Jul; 115():4-12. PubMed ID: 31082692
[TBL] [Abstract][Full Text] [Related]
35. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
Furman RR; Eradat HA; DiRienzo CG; Hofmeister CC; Hayman SR; Leonard JP; Coleman M; Advani R; Chanan-Khan A; Switzky J; Liao QM; Shah D; Jewell RC; Lisby S; Lin TS
Lancet Haematol; 2017 Jan; 4(1):e24-e34. PubMed ID: 27914971
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study.
Covens AL; Filiaci V; Gersell D; Lutman CV; Bonebrake A; Lee YC
Gynecol Oncol; 2011 Feb; 120(2):185-8. PubMed ID: 21075433
[TBL] [Abstract][Full Text] [Related]
37. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Herbst RS; Arquette M; Shin DM; Dicke K; Vokes EE; Azarnia N; Hong WK; Kies MS
J Clin Oncol; 2005 Aug; 23(24):5578-87. PubMed ID: 16009949
[TBL] [Abstract][Full Text] [Related]
38. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer.
McMeekin DS; Gordon A; Fowler J; Melemed A; Buller R; Burke T; Bloss J; Sabbatini P
Gynecol Oncol; 2003 Jul; 90(1):64-9. PubMed ID: 12821343
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group.
van Wijk FH; Lhommé C; Bolis G; Scotto di Palumbo V; Tumolo S; Nooij M; de Oliveira CF; Vermorken JB;
Eur J Cancer; 2003 Jan; 39(1):78-85. PubMed ID: 12504662
[TBL] [Abstract][Full Text] [Related]
40. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
Konecny GE; Finkler N; Garcia AA; Lorusso D; Lee PS; Rocconi RP; Fong PC; Squires M; Mishra K; Upalawanna A; Wang Y; Kristeleit R
Lancet Oncol; 2015 Jun; 16(6):686-94. PubMed ID: 25981814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]